|Source||Humanized (from mouse)|
|Molecular mass||144.88 kDa|
|(what is this?)|
Crenezumab is a humanized monoclonal antibody against human 1-40 and 1-42 Beta amyloid, which is being investigated as a treatment of Alzheimer's disease. Crenezumab was developed by the Swiss-based biopharmaceutical company AC Immune, which licensed the drug in 2006 to Genentech, Inc. Its original name RG7412 refers to its inventor at AC Immune.
In May 2012, it was announced that the efficacy of crenezumab will be tested in a five-year trial against early-onset Alzheimer's disease. The $100 million trial will be funded by Genentech, the Banner Alzheimer's Institute, and the National Institutes of Health. Participants in the study will be recruited from an extended family in and around Medellín, Colombia. Approximately one-third of the 5,000 family members carry an autosomal dominant allele of presenilin-1 (PSEN1) that causes the early-onset form of Alzheimer's disease. The trial will test the effect of the drug on 300 individuals who have the PSEN1 mutation, but do not yet show symptoms of the disease.
In November 2014 at CTAD conference in Philadelphia, phase II results for the Crenezumab ABBY and BLAZE studies were presented.
ABBY study, with clinical endpoints: failed to meet the co-primary endpoints
BLAZE study, with biomarker endpoint: showed no significant difference in primary biomarker endpoint of amyloid PET between treatment group and placebo study. Similarly volumetric MRI, CSF tau, FDG PET showed no significant difference.
- "Statement On A Nonproprietary Name Adopted By The USAN Council: Crenezumab". American Medical Association.
- "Roche Signs First Alzheimer's Deal Of 2011 As Crucial Progress Awaited"
- "Testing a Drug That May Stop Alzheimer’s Before It Starts"
- "Alzheimer’s Stalks a Colombian Family"
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|